BCL-2 gene promoter

The **BCL-2 gene promoter** is a regulatory DNA region upstream of the BCL-2 (B-cell CLL/lymphoma 2) gene, which encodes a mitochondrial membrane protein that inhibits apoptosis and promotes cell survival[1][2][4]. The human BCL-2 gene has two main promoters (P1 and P2); the major P1 promoter is GC-rich, contains multiple transcription start sites, and functions without a TATA box[1][2][4]. The P1 promoter region contains complex secondary DNA structures such as G-quadruplexes and i-motifs, which are targets for small molecules capable of modulating BCL-2 gene expression[1][3]. These regulatory elements are extensively studied because **BCL-2 protein overexpression, driven by its promoter, contributes to tumorigenesis and resistance to cancer therapies**[1][3][4]. However, the **BCL-2 gene promoter itself is not a protein or classic receptor/enzyme/target**, but rather a DNA sequence controlling gene expression. Drugs that interact with or modulate this promoter function indirectly affect BCL-2 protein levels and thus apoptosis, but the promoter is not itself a conventional therapeutic drug target. **Note on accuracy:** The "BCL-2 gene promoter" is **not a traditional drug target** like an enzyme, receptor, or protein, but rather a transcriptional regulatory DNA sequence. While it is subject to modulation by certain experimental small molecules, clinical drugs typically target the BCL-2 protein itself, not the promoter. If you need information about the protein target, search for "B-cell CLL/lymphoma 2 protein (BCL-2)."

Other names

BCL2 promoterB-cell CLL/lymphoma 2 promoterBCL2 P1 promoterBCL2 P2 promoter

Modulation of DNA secondary structures (G-quadruplex/i-motif stabilization) to suppress or enhance BCL-2 gene expression[1][3]